AMRXAmneal Pharmaceuticals, Inc.
Is the business good?
The checks split: 7 of 9 health tests passed and margins widening, but thin cash backing (0.6×) and returns that lean on debt.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating profit outpaces operating cash flow, watch accruals and working capital. Conversion is worsening vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Leverage-amplified, a high assets-to-equity ratio does much of the work. ROE 25% = margin × turnover × leverage.
Unless marked, from derived.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is AMRX?
Amneal Pharmaceuticals, Inc. earns 14% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 4.9 points above what the capital costs: growth creates value
- Operating margin
- 15%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q2 2026
- Cash conversion
- 0.56×
Cash conversion · 1.63× a year ago · the operating profit has not turned into cash yet
- Share count, year on year
- +1.8%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | 4.6% |
| FY2021 | 7.3% |
| FY2022 | −4.3% |
| FY2023 | 8.5% |
| FY2024 | 8.9% |
| FY2025 | 13% |
Details›
- Gross margin12 months to Q2 2026
- 39%
- Operating margin12 months to Q2 2026
- 15%
- Net margin12 months to Q2 2026
- 5.1%
- Free cash flow margin
- 4.1%
- R&D as % of revenue
- 5.6%
- Revenue, trailing twelve months
- $3.12B
- Free cash flow, trailing twelve months
- $128M
- Net income, trailing twelve months
- $157M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 14%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #16 of 41 by RyuScore